Gilead Sciences Inc (GILD.O)
21 Oct 2016
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|64||2016||Executive Chairman of the Board|
|54||2016||Chief Executive Officer, Director|
|53||2014||Chief Financial Officer, Executive Vice President|
|55||2016||Chief Operating Officer|
|60||2007||Executive Vice President - Research and Development, Chief Scientific Officer|
- BRIEF-Gilead Sciences says phase 2 study of GS-4997 in PAH did not achieve primary endpoint
- BRIEF-Gilead announces SVR12 rates from four phase 3 studies of combination of Sofosbuvir, Velpatasvir And Voxilaprevir
- BRIEF-Gilead sciences, WHO announce 5-year visceral leishmaniasis collaboration
- BRIEF-Gilead terminates phase 2/3 study of GS-5745 in patients with Ulcerative Colitis
- Allergan to buy Tobira in push for fatty liver disease drugs